232 related articles for article (PubMed ID: 34956082)
1. Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.
Straign DM; Ihle CL; Provera MD; Owens P
Front Endocrinol (Lausanne); 2021; 12():769316. PubMed ID: 34956082
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.
Virk MS; Alaee F; Petrigliano FA; Sugiyama O; Chatziioannou AF; Stout D; Dougall WC; Lieberman JR
Bone; 2011 Mar; 48(3):578-87. PubMed ID: 21073986
[TBL] [Abstract][Full Text] [Related]
3. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic protein pathway responses and alterations of osteogenesis in metastatic prostate cancers.
Provera MD; Straign DM; Karimpour P; Ihle CL; Owens P
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1707. PubMed ID: 36054271
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
6. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.
Hover LD; Young CD; Bhola NE; Wilson AJ; Khabele D; Hong CC; Moses HL; Owens P
Cancer Lett; 2015 Nov; 368(1):79-87. PubMed ID: 26235139
[TBL] [Abstract][Full Text] [Related]
7. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
[TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic proteins and their receptor signaling in prostate cancer.
Ye L; Lewis-Russell JM; Kyanaston HG; Jiang WG
Histol Histopathol; 2007 Oct; 22(10):1129-47. PubMed ID: 17616940
[TBL] [Abstract][Full Text] [Related]
9. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.
Autzen P; Robson CN; Bjartell A; Malcolm AJ; Johnson MI; Neal DE; Hamdy FC
Br J Cancer; 1998 Nov; 78(9):1219-23. PubMed ID: 9820184
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
11. A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer.
Yang S; Pham LK; Liao CP; Frenkel B; Reddi AH; Roy-Burman P
Cancer Res; 2008 Jan; 68(1):198-205. PubMed ID: 18172312
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
Gooding S; Olechnowicz SWZ; Morris EV; Armitage AE; Arezes J; Frost J; Repapi E; Edwards JR; Ashley N; Waugh C; Gray N; Martinez-Hackert E; Lim PJ; Pasricha SR; Knowles H; Mead AJ; Ramasamy K; Drakesmith H; Edwards CM
Nat Commun; 2019 Oct; 10(1):4533. PubMed ID: 31586071
[TBL] [Abstract][Full Text] [Related]
13. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients.
Ihle CL; Provera MD; Straign DM; Smith EE; Edgerton SM; Van Bokhoven A; Lucia MS; Owens P
J Immunother Cancer; 2019 Nov; 7(1):293. PubMed ID: 31703602
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.
Masuda H; Fukabori Y; Nakano K; Takezawa Y; CSuzuki T; Yamanaka H
Prostate; 2003 Mar; 54(4):268-74. PubMed ID: 12539225
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BMP signaling suppresses metastasis in mammary cancer.
Owens P; Pickup MW; Novitskiy SV; Giltnane JM; Gorska AE; Hopkins CR; Hong CC; Moses HL
Oncogene; 2015 May; 34(19):2437-49. PubMed ID: 24998846
[TBL] [Abstract][Full Text] [Related]
16. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.
Feeley BT; Liu NQ; Conduah AH; Krenek L; Roth K; Dougall WC; Huard J; Dubinett S; Lieberman JR
J Bone Miner Res; 2006 Oct; 21(10):1571-80. PubMed ID: 16995812
[TBL] [Abstract][Full Text] [Related]
17. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells.
Yang S; Zhong C; Frenkel B; Reddi AH; Roy-Burman P
Cancer Res; 2005 Jul; 65(13):5769-77. PubMed ID: 15994952
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Ye L; Lewis-Russell JM; Davies G; Sanders AJ; Kynaston H; Jiang WG
Int J Oncol; 2007 Feb; 30(2):521-9. PubMed ID: 17203235
[TBL] [Abstract][Full Text] [Related]
19. Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line.
Mishra S; Tang Y; Wang L; deGraffenried L; Yeh IT; Werner S; Troyer D; Copland JA; Sun LZ
Prostate; 2011 Sep; 71(13):1441-54. PubMed ID: 21321980
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
Haudenschild DR; Palmer SM; Moseley TA; You Z; Reddi AH
Cancer Res; 2004 Nov; 64(22):8276-84. PubMed ID: 15548695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
